Establishment and Validation of a Risk Score for the Early Prediction of COVID-19 Severity
Salam Bennouar*, Abdelghani Bachir Cherif, Amel Kessira, Djamel-Eddine Bennouar and Samia Abdi
Corresponding Author: Salam Bennouar, Central Laboratory of Clinical Biology, Frantz Fanon Hospital, University Hospital Center of Blida, Algeria 9000
Accepted: December 12th, 2020
Citation: Bennouar S, Cherif AB, Kessira A, Bennouar D & Abdi S. (2020) Establishment and Validation of A Risk Score for the Early Prediction of COVID-19 Severity. J Infect Dis Res, 3(S3): 25.
Copyrights: ©2020 Bennouar S, Cherif AB, Kessira A, Bennouar D & Abdi S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :
Background and Aims: Coronavirus disease 2019 is characterized by a spectrum of clinical severity ranging from asymptomatic to severe or even critical forms requiring intensive care services. In a previous published work, we have identified six biological abnormalities as potential risk markers independently related to the severity: Elevated urea nitrogen, elevated CRP, decreased natremia, decreased albumin, elevated LDH and elevated neutrophil to lymphocyte ratio. For a clinical convenience, this study aimed to establish a score system to identify high-risk individuals open admission, to validate this score in a separate cohort, but also to test its accuracy in the prediction of in-hospital mortality.

Methods: In this is retrospective, single-center, cohort study, data from 330 SARS-CoV-2 infected patients, who were admitted at the University Hospital of Blida, Algeria, were used to establish a risk score system to predict progression toward severity. Then, the same score was tested to predict mortality in the same cohort. In a second stage, data from 240 additional COVID-19 patients were used to validate this score. Accuracy of the score was measured by the area under the receiver operating characteristic curve (AUC).

In the establishment cohort, a stepwise increase in the incidence of both severity and mortality was observed with the increment of the risk score (p<0.0001). Conversely, a progressive decrease in the average survival duration was noted with the increment of the risk score (pANOVA<0.0001). A similar trend was confirmed when analyzing this association in the validation cohort (p<0.0001). The AUC in the validation cohort was 0.74 [0.66-0.82] and 0.90 [0.87-0.94], p<0.0001, respectively for severity and mortality prediction. 

This study provides a useful risk score based on biological routine parameters assessed at the time of admission, which has proven its effectiveness in predicting both severity and short-term mortality of COVID-19.

COVID-19, Risk score, Biomarkers, Severe COVID-19, Short-term mortality